Headlands Technologies LLC Has $1.72 Million Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Headlands Technologies LLC decreased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 43.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,003 shares of the company's stock after selling 54,581 shares during the quarter. Headlands Technologies LLC's holdings in Hims & Hers Health were worth $1,717,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Crewe Advisors LLC bought a new position in Hims & Hers Health during the fourth quarter worth about $28,000. Raleigh Capital Management Inc. boosted its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health in the fourth quarter worth $38,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $2.06 on Friday, hitting $25.93. 27,621,633 shares of the company's stock were exchanged, compared to its average volume of 14,730,901. The firm has a 50-day moving average price of $39.82 and a 200-day moving average price of $29.94. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The company has a market cap of $5.76 billion, a P/E ratio of 58.93 and a beta of 1.65.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the company's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the sale, the insider now owns 8,007 shares in the company, valued at $230,441.46. This represents a 21.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now owns 157,345 shares of the company's stock, valued at $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,078,738 shares of company stock valued at $38,386,521. 17.71% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on HIMS. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price target for the company. Bank of America increased their price target on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a report on Tuesday, March 18th. Needham & Company LLC lifted their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Citigroup reissued a "sell" rating and set a $27.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Finally, Piper Sandler lifted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.